Bayer and Regeneron Collaborated to Develop Novel Eye Disease Treatment Therapy
Bayer AG and Regeneron Pharmaceuticals, Inc. will collaboratively develop a combination therapy for significant eye diseases treatment. The combination therapy, REGN910-3 contains angiopoietin 2 (Ang2) antibody nesvacumab and vascular endothelial growth factor (VEGF) Trap-Eye aflibercept, administered to the patient as single intravitreal injection for treatment of patients with wet-age related macular degeneration or diabetic macular edema.
Regeneron’s angiopoietins belong to family of vascular growth factors which play a crucial role in development and maturation of blood vessels in the eye. VEGF proteins stimulates the formation of necessary blood vessels which supply nutrition to the tissues. The preliminary studies have shown that synergistic effect of angiopoietins and VEGF has promoted the formation and maturation of blood and lymphatic vessels of the eye showing the potential of development of new blood vessels and permeability of blood vessel walls in certain eye diseases.
Two separate Phase II clinical studies are going on to evaluate the efficacy of the combination therapy for wet-age related macular degeneration or diabetic macular edema. Their other collaborative product REGN2176-3 an antibody to platelet derived growth factor receptor beta (PDGFR-beta) co-formulated in a single intravitreal injection with aflibercept is also in Phase II clinical trial for wet age-related macular degeneration treatment. Apart from this Bayer and Regeneron collaborated for global development and commercialization of EYLEA Injections.
“Our collaboration with Bayer has been extremely successful to date, as we work together to combat vision loss around the world. Vision loss can often have devastating consequences to an individual’s quality of life,” said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. “This new agreement reflects our shared commitment to being leaders in ophthalmology and to now pursue the goal of improving anatomical and visual outcomes for patients with retinal eye diseases.”
This deal will provide Regeneron $50 million as upfront payment and will share the amount required for the global development program with Bayer. Bayer will receive exclusivity for commercialization of the product outside U.S. and profits will be shared with Regeneron equally. Whereas inside U.S. Regeneron holds the exclusive rights of the commercialization of the product with 100% rights on sales profit. Regeneron is also entitled to receive up to $80 million as potential payments pertaining to regulatory and development milestones.